2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163940
    LX1
    		Inhibitor 99.13%
    LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide (HY-70002), and the combination with Enzalutamide (HY-70002) further inhibits tumor growth.
    LX1
  • HY-150630
    ALR2-IN-1
    		Inhibitor 99.33%
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research.
    ALR2-IN-1
  • HY-118819
    5-Bromo-3-phenyl salicylic acid
    		Inhibitor 98.00%
    5-Bromo-3-phenyl salicylic acid is a selective inhibitor for human 20α-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 140 nM.
    5-Bromo-3-phenyl salicylic acid
  • HY-16433
    Risarestat
    		Inhibitor 98.09%
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.
    Risarestat
  • HY-N13759
    Mumeose K
    		Inhibitor
    Mumeose K is the inhibitor for aldose reductase with an IC50 of 27 μM. Mumeose K exhibits potential anti-diabetic activity, and can be used in research about diabetes-related complication.
    Mumeose K
  • HY-120208
    MK204
    		Inhibitor
    MK204 is an aldose reductase (AR) inhibitor that can be used in diabetes research.
    MK204
  • HY-N1517R
    Ganoderic acid C2 (Standard)
    Ganoderic acid C2 (Standard) is the analytical standard of Ganoderic acid C2. This product is intended for research and analytical applications. Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 is the inhibitor for aldose reductase with an IC50 of 43.8 µM.
    Ganoderic acid C2 (Standard)
  • HY-149254
    PTP1B/AKR1B1-IN-1
    		Inhibitor
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.
    PTP1B/AKR1B1-IN-1
  • HY-121933
    IDD388
    		Inhibitor 99.40%
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM).
    IDD388
  • HY-146574
    AKR1C3-IN-7
    		Inhibitor
    AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.19 μM. AKR1C3-IN-7 shows antitumor activity.
    AKR1C3-IN-7
  • HY-161839
    AKR1C2/3-IN-1
    		Inhibitor
    AKR1C2/3-IN-1 (compound 3a) is a potent AKR1C2 and AKR1C3 inhibitor with IC50 values of 90, 50 nM, respectively. AKR1C2/3-IN-1 can be used as a radiation sensitizer and as a potentiator of chemotherapy cytotoxicity.
    AKR1C2/3-IN-1
  • HY-151947
    ALR2-IN-3
    		Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
    ALR2-IN-3
  • HY-150650
    S07-2001
    		Inhibitor
    S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance.
    S07-2001
  • HY-131542
    APPA
    		Inhibitor
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research.
    APPA
  • HY-163610
    AKR1C3-IN-13
    		Inhibitor
    AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells.
    AKR1C3-IN-13
  • HY-N11639
    Ganoderic acid Df
    		Inhibitor
    Ganoderic acid Df is a lanostane-type triterpenoid, that can be isolated from the fruiting body of Ganoderma lucidum. Ganoderic acid Df potently inhibits aldose reductase, with an IC50 of 22.8 ± 0.6 μM.
    Ganoderic acid Df
  • HY-106877
    Minalrestat
    		Inhibitor
    Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes.
    Minalrestat
  • HY-146129
    Aldose reductase-IN-5
    As an aldose reductase (ALR2) inhibitor, the compound is used to enhance the combination of inhibitory excitability and antioxidant capacity to delay the progress of diabetes complications.
    Aldose reductase-IN-5
  • HY-149255
    PTP1B/AKR1B1-IN-2
    		Inhibitor
    PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM).
    PTP1B/AKR1B1-IN-2
  • HY-147977
    ALR1/2-IN-1
    		Inhibitor
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity.
    ALR1/2-IN-1
Cat. No. Product Name / Synonyms Application Reactivity